MedTrace Logo

Jet or Vibrating Mesh Nebulisation for Secretion Management in ICU

NCT05635903 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-02-02

No results posted yet for this study

Summary

Critically unwell patients in Intensive Care have a decreased ability to effectively clear secretions. High secretion load is a major risk factor in the failure of tracheal extubation failure and the requirement for reintubation. Extubation failure is a predictor of poor outcome independent of the severity of the underlying illness. Nebulisation of isotonic saline can be employed to manage secretions by reducing the secretion viscosity and facilitating clearance of respiratory sections during tracheal suction.

Standard jet nebulisers have been the mainstay of respiratory section management therapy in critical care since the early 1990s. A more recent development has been the vibrating mesh nebuliser. There is evidence of improved humidification and reduced water particle size and theoretically better transfer to the distal airways.

Conditions

Interventions

PROCEDURE

Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser

Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser

PROCEDURE

Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser

Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser

PROCEDURE

Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser

standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser

Sponsors & Collaborators

  • Aerogen

    collaborator INDUSTRY

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Malcolm Sim, MBcHB · nhs GGC health board

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-22
Primary Completion
2023-12-22
Completion
2023-12-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635903 on ClinicalTrials.gov